Can fiber-enhanced food products really improve our health? - Orange County Register
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Over the past few decades, emerging evidence on the human microbiome has helped us make more informed nutritional choices. More recently social media trends have further shaped demand for foods and products to help optimize gut health. From bread and tortillas to protein bars, cereal, cookies and even soda, fiber is a major marketing strategy. Can these fiber products really improve our health?
Fiber recommendations are based on calorie needs, but a good general target is about 14 grams for every 1,000 calories eaten. For many adults, that is about 25 to 38 grams of fiber daily. Fiber helps keep our digestive systems moving and higher fiber intake is associated with better heart health, including lower cholesterol and reduced cardiovascular risk.
This article is an excerpt. To read the full content, visit the original source. Orange County Register
Related articles
Student feedback shapes enhanced mental health supports - Brock University
Member of Provincial Parliament for Niagara West Sam Oosterhoff (left) visited Brock to congratulate the Student Wellness and Accessibility Centre (SWAC) team on new provincial funding to support mental health services. From left are Oosterhoff; Associate Vice-President, Students Brad Clarke; Executive Director, Student Wellness and Accessibility Centre Bill Helmeczi; Manager, Health and Clinical Operations Kerri Nagy; Vice-President, External Alexandra Lawson; and Project Manager, Special Programs Renata Faber. Drawing on feedback from the Brock community, the Student Wellness and Accessibility Centre (SWAC) is refreshing the delivery of mental health services to provide more personalized support.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.
Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress
Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.
TheBodyPro | What to know about hepatitis B when switching to tenofovir-sparing antiretroviral regimens - European AIDS Treatment Group
TheBodyPro clinical overviewAs we more frequently prescribe injectables, two-drug therapies, and other novel antiretroviral regimens, a growing proportion of those regimens lack tenofovir. Because tenofovir is used to treat hepatitis B virus (HBV) and is partially protective against new HBV infection, providers need to consider the risk of new or reactivated HBV before switching a patient to a tenofovir-sparing regimen. “I think we are very much in, and entering, an era where increasingly more therapeutic options for antiretroviral therapy and PrEP are going to be without tenofovir,” said H. Nina Kim, M. D., M. Sc., a professor of medicine at University of Washington’s Division of Allergy and Infectious Diseases. Kim co-authored a viewpoint paper this May in Clinical Infectious Diseases highlighting the issue so that clinicians can protect patients against potentially harmful reactivations and new HBV infections. “Many of these reactivations may be subclinical with mild rise in liver enzymes,” Kim said.
0 comments
No comments yet. Be the first to share your thoughts!